# Immvira Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immvira-co

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.immvira-theravir.com
- Total disclosed funding: $83M
- Latest round: Series C (Dec 31, 2020)
- Investors on record: 17

## About

Founded in 2015 and based in Shenzhen, China, Immvira Co., Ltd. is a biotechnology company that focuses on the R&D of anti-cancer drug vectors. In 2020, the MVR-T3011 Phase I clinical trial began to do in China and Australia. In 2021, the MVR-T3011 IT phase II received the first patient enrolled (FPI) in China and the US, and MVR-T3011 IV received Investigational New Drug (IND) approval in China. Dr. Grace Zhou, the company's CEO, developed engineering recombinant oncolytic herpes simplex viruses (OHSV) technology to treat cancer.

Immvira Co., Ltd. provides anti-cancer drug vectors based on OHSV technology. Anti-cancer drug vectors include replicating and non-replicating herpes simplex virus vectors, drug delivery exosomes, and tumor vaccines. And drug delivery methods include intravenous, intraperitoneal, pleural, and vesical injections. Its three oncolytic virus products have been in phase I and phase II clinical trials.

## Funding rounds

- Series C, Dec 31, 2020 — OrbiMed Advisors, China Merchants Capital, WinDigital Capital, Lan Ting Capital, GL Ventures, Octagon Capital Advisors, Greater Bay Area Homeland Investments
- Series B, Sep 23, 2020, $10M — Shanghai Healthcare Capital
- Series B, Jun 15, 2020, $58M — Cowin Capital, Huagai Capital, Apricot Capital, GL Ventures
- Series A, Jan 31, 2019, $15M — Yonghua Capital, Leaguer Group, Triwise Capital, MED-FINE Capital, TF Capital, Bohe Angel Fund
- Series A, Sep 13, 2016 — Yonghua Capital, Triwise Capital, TF Capital

## Investors

- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series A
- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Series A
- TF Capital — Series A
- Leaguer Group (https://capitalatlas.ai/funds/leaguer-group) — Series A
- MED-FINE Capital (https://capitalatlas.ai/funds/med-fine-capital) — Series A
- Bohe Angel Fund — Series A
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series B
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series B
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B, Series C
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- China Merchants Capital (https://capitalatlas.ai/funds/china-merchants-capital) — Series C
- WinDigital Capital (https://capitalatlas.ai/funds/windigital-capital) — Series C
- Lan Ting Capital — Series C
- Octagon Capital Advisors (https://capitalatlas.ai/funds/octagon-capital-advisors) — Series C
- Greater Bay Area Homeland Investments — Series C